ArticleMolecular cancer research : MCR2015
LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.
Article in Molecular cancer research : MCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- High expression of LEF1 correlates with poor prognosis in solid tumors, but not blood tumors: a meta-analysis.Bioscience reports · 2020Pooled it
- The Potential of MicroRNAs as Prostate Cancer Biomarkers.European urology · 2016Pooled it
- Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity.Journal of translational medicine · 2026Review
- Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology.Molecular oncology · 2025Article
- Integrative analysis of exosomal ncRNAs and their regulatory networks in liver cancer progression.Practical laboratory medicine · 2025Article
- Article
- Analysis of immune infiltration in basal cell carcinoma based on transcriptome sequencing and experimental validation of diagnostic biomarkers.Discover oncology · 2025Article
- Suppression of Cellular Proliferation in PC3 Prostate Cancer Cells by Green Tea Extract Through Induction of miR-34a Expression.Food science & nutrition · 2025Article
- Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation.Molecular cancer · 2025Review
- Identification of novel gut microbiota-related biomarkers in cerebral hemorrhagic stroke.Frontiers in medicine · 2025Article
- Research Progress of LEF1 Gene in Malignant Tumors.Clinical Medicine Insights. Oncology · 2025Review
- MicroRNA in prostate cancer: from biogenesis to applicative potential.BMC urology · 2024Review
- The effect of miR-23b-3p on regulating GH by targeting POU1F1 in Yanbian yellow cattle.Animal biotechnology · 2024Article
- Bioinformatics-Assisted Extraction of All PCa miRNAs and their Target Genes.MicroRNA (Shariqah, United Arab Emirates) · 2024Article
- MiR-34a functions as a tumor suppressor in oral cancer through the inhibition of the Axl/Akt/GSK-3β pathway.Journal of dental sciences · 2024Article
- MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer.Translational oncology · 2023Article
- Biomarker potential of the LEF1/TCF family members in breast cancer: Bioinformatic investigation on expression and clinical significance.Genetics and molecular biology · 2023Article
- Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway.Frontiers in pharmacology · 2023Review
- An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?Veterinary sciences · 2022Review
- Efficacy of green tea extract on PC3 prostate cancer cells through upregulation of miR-195 expression and suppression of epithelial to mesenchymal transition.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
unlabelledThe microRNA-34a (miR-34a), a tumor-suppressive microRNA (miRNA), is implicated in epithelial-mesenchymal transition (EMT) and cancer stem cells. Lymphoid enhancer-binding factor-1 (LEF1) is a key transcription factor in the Wnt signaling pathway, and has been suggested to be involved in regulation of cell proliferation and invasion. Here, the molecular mechanism of miR-34a and LEF1 in cooperatively regulating prostate cancer cell invasion is described. Molecular profiling analysis of miRNA levels in prostate cancer cells revealed a negative correlation between miR-34a and LEF1 expression, and the downregulation of LEF1 by miR-34a was confirmed by luciferase assays. Furthermore, miR-34a specifically repressed LEF1 expression through direct binding to its 3'-untranslated regions (3'-UTR). miR-34a modulated the levels of LEF1 to regulate EMT in prostate cancer cells. Functionally, miR-34a negatively correlated with the migration and invasion of prostate cancer cells through LEF1. An analysis of miR-34a expression levels in matched human tumor and benign tissues demonstrated consistent and statistically significant downregulation of miR-34a in primary prostate cancer specimens. These data strongly suggest that miR-34a/LEF1 regulation of EMT plays an important role in prostate cancer migration and invasion. IMPLICATIONS: The miR-34a-LEF1 axis represents a potential molecular target for novel therapeutic strategies in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.